A review of German Scedosporium prolificans cases from 1993 to 2007

K Tintelnot1, G Just-Nübling, R Horré

  • 1Division of Mycology, Robert Koch-Institut, Nordufer 20, Berlin, Germany. tintelnotk@rki.de

Medical Mycology
|March 21, 2009
PubMed

Insights

Scedosporium prolificans, a resistant fungal pathogen, caused fatal invasive infections in 12 of 13 immunocompromised patients. Molecular analysis revealed genetic diversity within S. prolificans strains.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Molecular Biology

Background:

  • Scedosporium prolificans is a highly resistant fungal opportunistic pathogen.
  • It is geographically limited, primarily found in Australia, USA, and Spain, with reported cases elsewhere.
  • Infections pose a significant threat, especially to immunocompromised individuals.

Purpose of the Study:

  • To retrospectively review Scedosporium prolificans infections and colonization in Germany.
  • To investigate the genetic diversity of S. prolificans isolates using molecular methods.

Main Methods:

  • Retrospective review of 20 patients identified between August 1993 and May 2007.
  • Molecular analysis of ribosomal DNA (rDNA) regions (18S, ITS, 28S D1/D2).
  • Sequencing of translation elongation factor EF1-alpha (EF-1alpha) and chitin synthase (CHS-1) genes.

Main Results:

  • Twelve of 13 patients with hematological disorders or immunosuppressive therapy experienced fatal invasive scedosporiosis.
  • Respiratory tract colonization was observed in transplant recipients, cystic fibrosis patients, and individuals with sinusitis.
  • rDNA regions were monomorphic, but EF-1alpha and CHS-1 genes showed genotypic variations (3 and 2 genotypes, respectively).

Conclusions:

  • Scedosporium prolificans poses a severe threat, particularly to immunocompromised patients, often leading to fatal outcomes.
  • Genetic analysis using EF-1alpha and CHS-1 genes is valuable for differentiating S. prolificans strains.
  • Further research into S. prolificans epidemiology and treatment is warranted.